Curated News
By: NewsRamp Editorial Staff
November 13, 2026
Demystifying Clinical Trials for IBD: Foundation Calls for Diverse Participation
TLDR
- Early clinical trial participation gives IBD patients access to new treatments before FDA approval and a chance to shape future standards of care.
- Clinical trials progress through four phases testing safety, effectiveness, comparison to standard treatments, and long-term real-world monitoring.
- The Crohn's & Colitis Foundation aims to make IBD clinical trials more accessible and representative, offering hope for better treatments and healthier lives.
- Nearly 1 in 100 Americans has inflammatory bowel disease, and clinical trials can study medications, diets, or emotional impacts of living with the condition.
Impact - Why it Matters
Clinical trials are the backbone of medical progress, yet they often struggle to enroll enough participants, especially from diverse backgrounds. This news matters because it sheds light on the critical role that underrepresented communities play in advancing research for inflammatory bowel disease (IBD), a condition affecting nearly 1 in 100 Americans. By understanding the phases of trials and addressing common misconceptions, patients can make informed decisions about participation. Increased diversity in trials leads to more generalizable results and ensures that new treatments work for everyone. For the millions living with IBD, participation not only offers access to cutting-edge therapies but also contributes to a collective effort to find better treatments and ultimately a cure. The Crohn’s & Colitis Foundation’s push for transparency and accessibility empowers patients to take an active role in shaping the future of IBD care.
Summary
For the nearly 1 in 100 Americans living with inflammatory bowel disease (IBD), clinical trials offer a pathway to better treatments and improved quality of life. Yet many trials face delays due to lack of enrollment, particularly among underrepresented communities. In a recent announcement, the Crohn’s & Colitis Foundation aims to demystify the clinical trial process and encourage participation. A study by the Foundation highlights the prevalence of IBD, which includes Crohn’s disease and ulcerative colitis, and underscores the need for research that can lead to new therapies.
Dr. Ruby Greywoode, a gastroenterologist at Montefiore Medical Center, emphasizes the importance of diverse participation: “We need more people to get involved in clinical trials, especially those from underrepresented communities, including people of color and older adults, who have some of the highest rates of chronic disease.” The news release explains the four phases of clinical trials, from initial safety testing in small groups to post-approval monitoring in thousands of patients. It also addresses common concerns such as cost, time commitment, and the ability to withdraw at any time. For those interested in IBD research, the Foundation provides resources to search for opportunities at crohnscolitisfoundation.org/clinical-trials-community.
By increasing awareness and accessibility, the Crohn’s & Colitis Foundation hopes to accelerate research and bring new treatments to the millions affected by IBD. As Dr. Greywoode notes, “Clinical trials give patients a real way to shape the future of treatment. It’s not just about their own care; it can help others, too.”
Source Statement
This curated news summary relied on content distributed by Noticias Newswire. Read the original source here, Demystifying Clinical Trials for IBD: Foundation Calls for Diverse Participation
